Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole MR maintenance in healed erosive esophagitis
NCT00321737Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2006
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of dexlansoprazole in erosive esophagitis (EE) (3 arms), sponsored by Takeda. Primary endpoint: Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy at 6 months. Started May 2006; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT00321737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321737.